Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Devin Razavi‐Shearer(University of London), Carlos Eduardo Brandão‐Mello(Universidade Federal do Estado do Rio de Janeiro), Khalid Al‐Naamani, Tarik Asselah(Inserm), Monique Andersson, Kostas Athanasakis, Abdulrahman Aljumah, Amarsanaa Jazag, Ivane Gamkrelidze, Seyed Moayed Alavian(Baqiyatallah University of Medical Sciences), Oidov Baatarkhuu(Mongolian Academy of Sciences), Jidong Jia(Beijing Friendship Hospital), Inka Aho(Helsinki University Hospital), Soo Aleman(Karolinska University Hospital), Aïcha Bensalem, Abdul Rahman Bizri, Ponsiano Ocama, Sarah Blach(Center for Disease Analysis), Calvin Q. Pan, Ziv Ben‐Ari, N. Masri, Richard T. Gray, Ulus Salih Akarca(Ege University), Zaigham Abbas(Ziauddin University), Motswedi Anderson, Ayat R. Abdallah, Ahmad Al‐Rifai, Thomas Berg, Faleh Z. Al-Faleh, Sang Hoon Ahn, Hailemichael Desalegn(St. Paul's Hospital Millennium Medical College), Wornei Silva Miranda Braga, Ibrahim Altraif, Abduljaleel Alalwan, Waleed K. Al‐Hamoudi, Alessio Aghemo, Carol Brosgart(Gilead Sciences (United States)), Sabohat Ahmadbekova
˜The œLancet. Gastroenterology & hepatology
July 27, 2023
10.1016/s2468-1253(23)00197-8
Cited by 399

Related Papers

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).
|Gastroenterology|2003|554
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|˜The œLancet. Gastroenterology & hepatology|2019|539
World Gastroenterology Organisation Global Guidelines
|Journal of Clinical Gastroenterology|2014|521